Boston Scientific Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/9/2026)
| Balance Sheet | Total Assets | 43,673,000,000.00 | ROE | 55.49 % |
| Balance Sheet | Total Equity | 24,233,000,000.00 | ROA | 6.64 % |
| Cashflow | Capital Expenditures | -876,000,000.00 | P/FCF | 17.57 |
| Cashflow | Free Cash Flow | 3,657,999,872.00 | – | – |
| Cashflow | Operating Cash Flow | 4,534,000,000.00 | P/CF | 14.17 |
| Income | Earnings per Share (diluted) | 1.94 | Div. Yield | – |
| Income | Net Income | 2,897,000,000.00 | P/E | 22.16 |
| Income | Shares Outstanding | 1,494,500,000.00 | P/B | 2.65 |
| Income | Total Revenue | 20,074,000,000.00 | P/S | 3.20 |
Ratios calculated on: 10/14/2026
Company Description
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women's Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System. In November 2013, the Company announced that it has acquired Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.bostonscientific.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more